A Phase 4 interventional study of Sodium Carboxymethylcellulose and Levofloxacin in Dry Eye Syndromes and Cataract, sponsored by Allergan. Completed at 1 site in China. Open to participants aged 60 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-04-23.
Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing carboxymethylcellulose in Dry Eye Syndromes — 2 open to participants now, 2 under way, none of them phase 3. carboxymethylcellulose · Dry Eye Syndromes.
Among the 12 studies testing carboxymethylcellulose in Dry Eye Syndromes, this one is the 2nd largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2011, is one of 11 in phase 4, and was the 8th registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.
Browse Dry Eye Syndromes studies →2 of the 12 studies testing carboxymethylcellulose in Dry Eye Syndromes are open now, in 2 countries. Recruiting first, the newest first:
Andover Research Eye Institute · Sites in United States
Ages 18+
Pokhara Academy of Health Sciences, Western Regional Hospital · Sites in Nepal
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 60 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 180 is above the median of 60 across 1,129 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 80 across the 11 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 12 have an industry lead sponsor. The 7 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
48 studies in Dry Eye Syndromes by AbbVie: 1 open now, 1 under way, none of them phase 3. Of 47 finished, 40 (85%) have results posted.
Among the 48 studies in Dry Eye Syndromes by AbbVie, this one is the 16th largest by enrollment of the 40 interventional ones that give a count, is one of 3 that started in 2011, is one of 9 in phase 4, and was the 24th registered.
AbbVie’s Dry Eye Syndromes studies by the year they started, since 2001.
1 of the studies testing carboxymethylcellulose in Dry Eye Syndromes that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07635849Pokhara Academy of Health Sciences, Western Regional HospitalRandomized Clinical Trial of Artificial Tears With and Without Preservatives in Patients With Dry Eye Disease | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing carboxymethylcellulose in Dry Eye Syndromes, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 48 in Dry Eye Syndromes:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the effect of sodium carboxymethylcellulose eye drops in the treatment of dry eye after cataract surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Sodium carboxymethylcellulose (Refresh Liquigel®) 1 drop in the study eye 4 times a day for 30 days plus conventional therapy of levofloxacin for 7 days post-cataract surgery and prednisolone for 30 days post-cataract surgery each in the study eye up to 4 times a day.
Drug: Sodium Carboxymethylcellulose · Drug: Levofloxacin · Drug: Prednisolone
Conventional therapy of levofloxacin for 7 days post-cataract surgery and prednisolone for 30 days post-cataract surgery each in the study eye up to 4 times a day.
Drug: Levofloxacin · Drug: Prednisolone
Sodium carboxymethylcellulose (Refresh Liquigel®) 1 drop in the study eye 4 times a day for 30 days post-cataract surgery.
Also known as: Refresh Liquigel®
Levofloxacin 1 drop in the study eye 3 times a day for 7 days post-cataract surgery.
Also known as: Cravit®
Prednisolone 1 drop in the study eye 4 times a day for the 1st week post surgery, 3 times a day for the 2nd week post surgery, 2 times a day for the 3rd week post surgery, and 1 time a day for the 4th week post surgery.
Also known as: PRED FORTE®
Tear Break-Up Time (TBUT) in the Study Eye
TBUT is the time required for dry spots to appear on the surface of the study eye after blinking. The longer it takes, the more stable the tear film. A short TBUT is a sign of poor tear film.
Time frame: Day 7
Tear Break-Up Time (TBUT) in the Study Eye
TBUT is the time required for dry spots to appear on the surface of the study eye after blinking. The longer it takes, the more stable the tear film. A short TBUT is a sign of poor tear film.
Time frame: Day 30
Fluorescein Staining Score in the Study Eye
The cornea is evaluated following ocular administration of fluorescein stain in the study eye. The cornea is the transparent front part of the eye which covers the iris and pupil. The cornea is divided into 3 regions. Each region is scored according to the extent of staining, with scores ranging from 0 to 3 points: 0=non-staining, 1=staining range \< 1/2 of the cornea, 2=staining range ≥ 1/2 of the cornea, and 3=regional whole staining of the cornea. The total score ranges from 0 to 9 points. The higher the staining score, the worse the dry eye condition.
Time frame: Day 7, Day 30
Lissamine Green Staining Score in the Study Eye
Conjunctival and corneal staining are evaluated following ocular administration of lissamine green dye in the study eye. The conjunctiva is the clear membrane covering the white surface of the eye. The cornea is the transparent front part of the eye which covers the iris and pupil. The conjunctiva and cornea are divided into 5 regions that are scored based on the extent of staining. Scores range from 0 to 3 points: 0=non-staining, 1=staining range \< 1/2 of the conjunctiva and cornea, 2=staining range ≥ 1/2 of the conjunctiva and cornea, and 3=regional whole staining of the conjunctiva and cornea. The total score ranges from 0 to 15 points. The higher the grade score, the worse the dry eye condition.
Time frame: Day 7, Day 30
Results of Schirmer I Test With Anesthetics in the Study Eye
The Schirmer I test consists of anesthetic drops being placed into the lower eyelid of the study eye. Patients then close their eyes. Test paper is placed on the lower eyelid of the patient's closed eyes. The paper is then removed and the moisture length on the paper recorded. Shorter distances indicate worse dry eye symptoms.
Time frame: Day 7, Day 30
Ocular Surface Disease Index (OSDI) Questionnaire Score in the Study Eye
The OSDI is a 12-question survey for patients to document their dry eye disease symptoms in the study eye. The OSDI consists of a 5-point scale (0=none of the time and 4 = all of the time), with higher scores representing greater disability. The scores are totaled over the 12 questions and converted to a score of 0-100 (0=no disability and 100=complete disability).
Time frame: Day 7, Day 30
Subjective Symptom Total Score in the Study Eye
The following 11 subjective symptoms are evaluated in the study eye: foreign body sensation, photophobia, itching, pain in the eye, dry eye, eye heaviness, blurred vision, eye fatigue, eye discomfort, eye secretions and tears. Each of these symptoms is divided into 4 classes: no symptom=0; occasional symptoms=1; intermittent mild symptoms=2; and persistent obvious symptoms=3. The total score ranged from 0 (best) to 33 (worst).
Time frame: Day 7, Day 30
| Milestone | Sodium Carboxymethylcellulose and Conventional Therapy | Conventional Therapy |
|---|---|---|
| Started | 90 | 90 |
| Completed | 83 | 82 |
| Not completed | 7 | 8 |
TBUT is the time required for dry spots to appear on the surface of the study eye after blinking. The longer it takes, the more stable the tear film. A short TBUT is a sign of poor tear film.
| Seconds | Sodium Carboxymethylcellulose and Conventional Therapy | Conventional Therapy |
|---|---|---|
| Tear Break-Up Time (TBUT) in the Study Eye | 8.5 ± 5.5 | 6.6 ± 3.8 |
TBUT is the time required for dry spots to appear on the surface of the study eye after blinking. The longer it takes, the more stable the tear film. A short TBUT is a sign of poor tear film.
| Seconds | Sodium Carboxymethylcellulose and Conventional Therapy | Conventional Therapy |
|---|---|---|
| Tear Break-Up Time (TBUT) in the Study Eye | 9.0 ± 5.9 | 6.7 ± 4.8 |
The cornea is evaluated following ocular administration of fluorescein stain in the study eye. The cornea is the transparent front part of the eye which covers the iris and pupil. The cornea is divided into 3 regions. Each region is scored according to the extent of staining, with scores ranging from 0 to 3 points: 0=non-staining, 1=staining range \< 1/2 of the cornea, 2=staining range ≥ 1/2 of the cornea, and 3=regional whole staining of the cornea. The total score ranges from 0 to 9 points. The higher the staining score, the worse the dry eye condition.
| Scores on a Scale | Sodium Carboxymethylcellulose and Conventional Therapy | Conventional Therapy |
|---|---|---|
| Day 7 | 2.0 ± 2.8 | 1.8 ± 2.6 |
| Day 30 (N=83, 82) | 1.1 ± 1.8 | 1.2 ± 1.9 |
Conjunctival and corneal staining are evaluated following ocular administration of lissamine green dye in the study eye. The conjunctiva is the clear membrane covering the white surface of the eye. The cornea is the transparent front part of the eye which covers the iris and pupil. The conjunctiva and cornea are divided into 5 regions that are scored based on the extent of staining. Scores range from 0 to 3 points: 0=non-staining, 1=staining range \< 1/2 of the conjunctiva and cornea, 2=staining range ≥ 1/2 of the conjunctiva and cornea, and 3=regional whole staining of the conjunctiva and cornea. The total score ranges from 0 to 15 points. The higher the grade score, the worse the dry eye condition.
| Scores on a Scale | Sodium Carboxymethylcellulose and Conventional Therapy | Conventional Therapy |
|---|---|---|
| Day 7 | 2.9 ± 3.3 | 2.6 ± 3.2 |
| Day 30 (N=83,82) | 2.1 ± 2.4 | 2.3 ± 2.6 |
The Schirmer I test consists of anesthetic drops being placed into the lower eyelid of the study eye. Patients then close their eyes. Test paper is placed on the lower eyelid of the patient's closed eyes. The paper is then removed and the moisture length on the paper recorded. Shorter distances indicate worse dry eye symptoms.
| Millimeters | Sodium Carboxymethylcellulose and Conventional Therapy | Conventional Therapy |
|---|---|---|
| Day 7 | 11.8 ± 5.6 | 12.5 ± 6.8 |
| Day 30 (N=83, 82) | 12.7 ± 6.1 | 12.6 ± 6.5 |
The OSDI is a 12-question survey for patients to document their dry eye disease symptoms in the study eye. The OSDI consists of a 5-point scale (0=none of the time and 4 = all of the time), with higher scores representing greater disability. The scores are totaled over the 12 questions and converted to a score of 0-100 (0=no disability and 100=complete disability).
| Scores on a Scale | Sodium Carboxymethylcellulose and Conventional Therapy | Conventional Therapy |
|---|---|---|
| Day 7 | 15.6 ± 16.8 | 18.1 ± 19.5 |
| Day 30 (N=83, 82) | 12.7 ± 11.3 | 14.2 ± 13.8 |
The following 11 subjective symptoms are evaluated in the study eye: foreign body sensation, photophobia, itching, pain in the eye, dry eye, eye heaviness, blurred vision, eye fatigue, eye discomfort, eye secretions and tears. Each of these symptoms is divided into 4 classes: no symptom=0; occasional symptoms=1; intermittent mild symptoms=2; and persistent obvious symptoms=3. The total score ranged from 0 (best) to 33 (worst).
| Scores on a Scale | Sodium Carboxymethylcellulose and Conventional Therapy | Conventional Therapy |
|---|---|---|
| Day 7 | 6.1 ± 5.3 | 6.4 ± 5.2 |
| Day 30 (N=83, 82) | 5.1 ± 3.6 | 5.6 ± 4.0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sodium Carboxymethylcellulose and Conventional Therapy | — | 0/86 (0%) | 0/86 (0%) |
| Conventional Therapy | — | 0/85 (0%) | 0/85 (0%) |
| Age, Continuous(Years) | Sodium Carboxymethylcellulose and Conventional Therapy | Conventional Therapy | Total |
|---|---|---|---|
| Mean | 68.8 ± 7.1 | 69.0 ± 7.1 | 68.9 ± 7.1 |
| Sex: Female, Male(Participants) | Sodium Carboxymethylcellulose and Conventional Therapy | Conventional Therapy | Total |
|---|---|---|---|
| Female | 54 | 59 | 113 |
| Male | 36 | 31 | 67 |
The record gives a start of Jul 2011, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2014, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Carboxymethylcellulose